Answers are grounded in this paper and cite their sources.
Systematic review reveals laparoscopic sleeve gastrectomy offers greater weight loss than endoscopic sleeve gastroplasty, indicating different roles in obesity management.
Abstract Background: Restrictive bariatric procedures such as Laparoscopic Sleeve Gastrectomy (LSG) and Endoscopic Sleeve Gastroplasty (ESG) are increasingly utilized to address obesity and its comorbidities. LSG is a well-established and widely adopted bariatric procedure, whereas ESG, supported by recent technological advancements, is increasingly being utilized as a treatment option for obesity. Comparative evaluation of their outcomes is essential to guide clinical decision-making. Objective: To systematically review and synthesize evidence from randomized controlled trials (RCTs), meta-analyses, and registry data comparing ESG and LSG in terms of weight loss efficacy, safety, recovery time, economic impact, and impact on obesity-related comorbidities. Methods: A systematic search was conducted across PubMed, Embase, Scopus, and Cochrane Library for studies published between January 2020 and July 2025. Inclusion criteria were RCTs, meta-analyses, and registry-based studies reporting comparative outcomes for ESG and LSG. Data extraction focused on total body weight loss (TBWL), excess weight loss (EWL), complication rates, recovery time, economic implications, and hormonal/metabolic changes. Risk of bias was assessed using Cochrane RoB 2, and certainty of evidence was graded using GRADE methodology. Results: LSG demonstrated superior long-term EWL (60–70%) and TBWL (25–30%) at 2–5 years (1–3). ESG showed moderate efficacy with TBWL of 13–16% and EWL of 35–45% at 12 months, sustained up to 3 years (4,9). ESG had lower serious adverse event rates (<2%) and faster recovery (2–3 days) compared to LSG (5–10% adverse events; 2–6 weeks recovery) (1,3,13). Both procedures improved glycaemic control, hypertension, and NAFLD, with LSG showing greater metabolic remission (2,6,13). Hormonal analyses revealed distinct patterns: LSG reduced ghrelin and increased PYY and adiponectin; ESG preserved ghrelin levels and improved insulin secretory dynamics (9,10,11). Conclusion: ESG offers a safe, outpatient alternative to LSG with moderate efficacy, rapid recovery and potential short-term economic benefits . LSG remains superior in long-term weight loss and metabolic impact. ESG may serve as a complementary option in tiered obesity management. Further head-to-head trials and mechanistic studies are warranted.
No takes yet. Share an insight, caveat, or question.
Tripathi et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: